Citations

Clear

6273 citation(s) found for "To, Andrew".

So I Guess I Am a Device? Making the Case for Professional Practice in the Context of the FDA’s Final Rule on Laboratory-Developed Tests
Bryan, Andrew , Grys, Thomas E. , Graf, Erin H. , Grys, Thomas E , Bryan, Andrew

Mayo Clinic

The Journal of Applied Laboratory Medicine | September 19, 2024 | Volume: 10 | Issue: 2 | Pages: 517-519

10.1093/jalm/jfae100 | PMID 39297488 Get It

Impact of high-sensitivity cardiac troponin I assay imprecision on the safety of a single-sample rule-out approach for myocardial infarction
Li, Ziwen , Tew, Yong Yong , Kavsak, Peter A. , Aakre, Kristin M. , Jaffe, Allan S. , Apple, Fred S. , Collinson, Paul , Mills, Nicholas L. , Chapman, Andrew R. , Collinson, Paul O , Mills, Nicholas L , Aakre, Kristin M , Jaffe, Allan S. , Kavsak, Peter , Apple, Fred S.

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | September 19, 2024 | Volume: 63 | Issue: 3 | Pages: e59-e62

10.1515/cclm-2024-1011 | PMID 39297509 Get It

Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski, Hanna , Mehta, Shraddha S., Manigat, Laryssa, Kaufman, Stephanie, Hou, Hypatia, Nalbantoglu, ILKe , Zhang, Xuchen , Curl, Emily, Taliano, Ross , Glickman, Jonathan N. , Resnick, Murray B. , Patel, Neel , Taylor, Cristin , Montalto, Michael , Beck, Andrew H. , Wack, Katy, Wack, Katy E , Kaufman, Stephanie, Kim, Tae Hun , Torbenson, Michael , Bédossa, Pierre

Mayo Clinic

The Journal of Pathology: Clinical Research | September 19, 2024 | Volume: 10 | Issue: 5 | Pages: No page available

10.1002/2056-4538.12395 | PMID 39294925 Get It

AbstractThe gold standard for enrollment and endpoint assessment in metabolic dysfunction‐associated steatosis clinical trials is histologic assessment of a liver biopsy performed on glass slides. However, obtaining the evaluations from several expert pathologists on glass is challenging, as shipping the slides around the country or around the world is time‐consuming and comes with the hazards of slide breakage. This study demonstrated that pathologic assessment of disease activity in steatohepatitis, performed using digital images on the AISight whole slide image management system, yields results that are comparable to those obtained using glass slides. The accuracy of scoring for steatohepatitis (nonalcoholic fatty liver disease activity score ≥4 with ≥1 for each feature and absence of atypical features suggestive of other liver disease) performed on the system was evaluated against scoring conducted on glass slides. Both methods were assessed for overall percent agreement with a consensus “ground truth” score (defined as the median score of a panel of three pathologists’ glass slides). Each case was also read by three different pathologists, once on glass and once digitally with a minimum 2‐week washout period between the modalities. It was demonstrated that the average agreement across three pathologists of digital scoring with ground truth was noninferior to the average agreement of glass scoring with ground truth [noninferiority margin: −0.05; difference: −0.001; 95% CI: (−0.027, 0.026); and p < 0.0001]. For each pathologist, there was a similar average agreement of digital and glass reads with glass ground truth (pathologist A, 0.843 and 0.849; pathologist B, 0.633 and 0.605; and pathologist C, 0.755 and 0.780). Here, we demonstrate that the accuracy of digital reads for steatohepatitis using digital images is equivalent to glass reads in the context of a clinical trial for scoring using the Clinical Research Network scoring system.
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Jensen, Jeffrey L. , Bobek, Olivia , Chan, Irenaeus C.C. , Miller, Brian C. , Hillman, David W. , Heller, Glenn , Druley, Todd E. , Armstrong, Andrew J. , Morris, Michael J. , Milowsky, Matthew I. , Beltran, Himisha , Coombs, Catherine C. , Druley, Todd , Bolton, Kelly L , Coombs, Catherine C , Morris, Michael J , Hillman, David W , Heller, Glenn , Bobek, Olivia , Armstrong, Andrew J , Bolton, Kelly L.

Mayo Clinic

Clinical Cancer Research | September 17, 2024 | Volume: 30 | Issue: 21 | Pages: 4910-4919

10.1158/1078-0432.ccr-24-0803 | PMID 39287426 Get It

Abstract Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (OS), predominantly through cardiovascular adverse events (CVAE). Because androgen receptor pathway inhibitors (ARPI) used in metastatic castration-resistant prostate cancer (mCRPC) are also associated with CVAEs and because CH negatively impacted survival in an advanced solid tumor cohort, we hypothesized that CH in mCRPC may be associated with increased CVAEs and inferior survival. Experimental Design: A targeted DNA sequencing panel captured common CH mutations in pretreatment blood samples from 957 patients enrolled in Alliance A031201: a randomized trial of enzalutamide ± abiraterone/prednisone in the first-line mCRPC setting. The primary outcome was the impact of CH on OS; the secondary outcomes were progression-free survival (PFS) and CVAEs. Results: Baseline comorbidities were similar by CH status. No differences in OS/progression-free survival were detected regardless of treatment arm or the variant allele frequency threshold used to define CH [primary: 2% (normal-CH, N-CH); exploratory: 0.5% (low-CH) and 10% (high-CH, H-CH)]. Patients with H-CH (7.2%) and TET2-mutated N-CH (6.0%) had greater odds of any CVAE (14.5% vs. 4.0%; P = 0.0004 and 12.3% vs. 4.2%; P = 0.010, respectively). More major CVAEs were observed in patients with H-CH (5.8% vs. 1.9%; P = 0.042) and N-CH (3.4% vs. 1.8%; P = 0.147). Conclusions: CH did not affect survival in patients with mCRPC treated with ARPIs in A031201. H-CH and TET2-mutated CH were associated with more CVAEs. These findings inform the risk/benefit discussion about ARPIs in mCRPC.
Teaching Video NeuroImage: Perivascular Tumefactive Neurosarcoidosis of the Basal Ganglia
Aboseif, Albert , Young, Nathan P. , McKeon, Andrew , McKeon, Andrew , Young, Nathan P , Aboseif, Albert

Mayo Clinic

Neurology | September 16, 2024 | Volume: 103 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000209899 | PMID 39284110 Get It

360.3: Predicting long-term outcomes in living kidney donor transplant recipients using deep learning algorithm-estimated medullary pyramid count: A novel biomarker.
Kline, Tim, Augustine, Joshua J. , Lerhrs, Tony, Issa, Naim , Riad, Samy , Đenić, Aleksandar , Augustine, Joshua , Mullan, Aidan F. , Rule, Andrew D.

Mayo Clinic

Transplantation | September 16, 2024 | Volume: 108 | Issue: 9S | Pages: No page available

10.1097/01.tp.0001065824.64857.4a Get It

Multi-Ingredient Pre-Workout Supplementation Does Not Influence Muscle Activation Following A Fatiguing Isokinetic Protocol
Connors, Benjamin R., Kowal, Rachel, Chomentowski, Peter J., Camic, Clayton L., Herring, Matthew, Kowal, Rachel, Sebastião, Émerson , Hill, Chris, Jagim, Andrew R.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2024 | Volume: 56 | Issue: 10S | Pages: 506-507

10.1249/01.mss.0001056888.95100.aa Get It

Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations
Hua, Le H. , Solomon, Andrew , Tenembaum, Sílvia , Rostásy, Kevin , Newsome, Scott D. , Marrie, Ruth Ann , Magyari, Melinda , Kantarci, Orhun H. , Cohen, Jeffrey A., Bove, Riley , Banwell, Brenda , Magyari, Melinda , Scalfari, Antonio , Rovira, Àlex , Hemmer, Bernhard , Hemingway, Cheryl , Harnegie, Mary Pat , Graves, Jennifer , Corboy, John R. , Waubant, Emmanuelle L.

Mayo Clinic

JAMA Neurology | September 16, 2024 | Volume: 81 | Issue: 11 | Pages: 1210

10.1001/jamaneurol.2024.3062 | PMID 39283621 Get It

Importance While the typical onset of multiple sclerosis (MS) occurs in early adulthood, 2% to 10% of cases initially present prior to age 18 years, and approximately 5% after age 50 years. Guidance on approaches to differential diagnosis in suspected MS specific to these 2 age groups is needed. Observations There are unique biological factors in children younger than 18 years and in adults older than age 50 years compared to typical adult-onset MS. These biological differences, particularly immunological and hormonal, may influence the clinical presentation of MS, resilience to neuronal injury, and differential diagnosis. While mimics of MS at the typical age at onset have been described, a comprehensive approach focused on the younger and older ends of the age spectrum has not been previously published. Conclusions and Relevance An international committee of MS experts in pediatric and adult MS was formed to provide consensus guidance on diagnostic approaches and key clinical and paraclinical red flags for non-MS diagnosis in children and older adults.
Differences In Body Fat Percentage And Minimum Wrestling Weight Values Between Ncaa And Naia Women’S Wrestlers
Opplinger, Robert A., Horswill, Craig A. , Dobbs, Ward C. , Fields, Jennifer B. , Bloomfield, Susan A. , Jones, Margaret T. , Jagim, Andrew R. , Tinsley, Grant M

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2024 | Volume: 56 | Issue: 10S | Pages: 818-818

10.1249/01.mss.0001059628.79858.83 Get It

Differences In BMD Z-scores Of Athletes Participating In Difference Sports Types
Magee, Meghan K., Fields, Jennifer B. , Lockard, B , Stroiney, Debra A., Jones, Margaret T. , Jagim, Andrew R.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 16, 2024 | Volume: 56 | Issue: 10S | Pages: 71-72

10.1249/01.mss.0001053104.98165.bd Get It